



**Glenmark Generics Limited launches its first product in the
United Kingdom**
- Launches Perindopril, an ACE inhibitor for symptomatic heart failure

Mumbai, November 6, 2008: Glenmark Generics Limited has announced that its European subsidiary has launched its first product in Western Europe via initiation of sales of Perindopril tablets in the United Kingdom.

Perindopril Erbumine, an ACE inhibitor indicated for symptomatic heart failure is being manufactured at the Glenmark Generics' plant in Goa, India. It is offered as tablets in three strengths 2, 4 and 8 mg. The total sales for this product segment for the calendar year 2007 was Euro 145 million (USD 210 mn) in the United Kingdom as stated by IMS Health.

Terrance Coughlin, Chief Executive Officer, Glenmark Generics Limited commented, "We are glad to have launched our first product for the UK market. We have done well in the US generics market and now Western Europe offers us another opportunity for growing our pure generics business. We see significant growth potential for Glenmark in this region. We will focus on developing a differentiated product portfolio which will encompass both oral solid and dermatology products. We believe that being vertically integrated with the API of Perindopril will give us a long term advantage over other generic players in the UK market."

Glenmark Generics' current portfolio in Europe consists of two approved products and eight Marketing Authorizations applications filed till date. The company is on track to make an additional eight product submissions in the second half of this financial year comprising both solid oral products and dermatology products. As part of its business plan, Glenmark Generics Europe seeks to grow its business in the European markets through a mix of its own product sales and out-licensing & supply opportunities with key generic companies



Glenmark Generics Limited

About Glenmark Generics Ltd. (GGL)

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, EU and Argentina and maintains marketing front-ends in these countries. GGL has a strong base in Formulations development with teams operating out of laboratories in India and Latin America. The Company has a state-of-the-art manufacturing plant at Goa, India that is approved by US FDA, TPD (Canada), MHRA, UK and many other overseas regulatory authorities. GGL also markets over 45 APIs to more than 80 countries across the world and had over 30 USDMFs filed and/or approved along with several Canadian DMFs, EDMFs and CEPs/CoSs. [www.glenmark-generics.com]

About Glenmark Pharmaceuticals Ltd:

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. Its shares are listed on India's two large stock exchanges, the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). It employs over 5500 people across its global operations over 85 countries. The Company is a leader in India in the discovery of new molecules and is focused in the areas of inflammation [Asthma/COPD, etc.], and metabolic disorders [Diabetes, Obesity, etc.]. The Company is in the process of creating marketing front-ends for the launch of its proprietary products in the future. Glenmark's first Asthma/COPD molecule, Oglemilast [GRC 3886], was licensed out to Forest Laboratories and Teijin Pharma Limited for the North American and Japanese markets, respectively, in two landmark deals. Oglemilast is presently undergoing Phase II clinical trials in the US. GRC 6211 has been out-licensed to Eli Lilly & company. For more information on GPL, log on to www.glenmarkpharma.com

For further information, please contact:

Jason D'Souza | Medha Satam
Glenmark, Mumbai, India
Tel: [+91 22] 40189919 / 40189993
Email : connect@glenmark-generics.com